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1. Introduction
This chapter addresses both carrier systems and biosensors which are often applied
directly to tissues, either as skin patches, implanted or ingested by a variety of routes.
It follows that there is a common theme between these applications and many of those
discussed elsewhere within this book. Any device, scaffold or implant within the body
must usually display extreme biocompatibility if it is not to cause harm to the patient.
The techniques of tailoring surfaces to ensure no adverse reactions are a common
theme running throughout this work on tissue engineering..
The first section of this chapter will describe the use of carrier systems in biomedical
applications. Initially a discussion is provided as to why carrier systems are required
and this is followed by descriptions of different classes of material of natural and
synthetic origin. This first section will continue with a description of how
nanotechnology is becoming utilised in carrier systems and will close with a
discussion of current and future applications of these materials.
2The second section of this chapter will be devoted to biosensors, beginning with a
history and descriptions of basic sensor formats. Glucose biosensors will be described
in more detail due to their dominance of the biosensor market. The construction of
first, second and third generation biosensors and their principle of operation will be
described. This will be followed by a description of the work progressing to the latest
devlopments for implantable glucose sensors and their potential for continuous
glucose monitoring. The chapter will close with a description of future needs
including warfarin monitoring and implantable organs.
2. Carrier systems
2.1 Introduction
In many instances a simple one-off administration of a drug will suffice, e.g. taking an
analgesic in response to a headache. However this simple approach is often
insufficient since often the condition may require continuous medication over a period
of time, with many conditions requiring long term drug therapy. Often a drug may
have an optimum concentration within the body; too low and no benefit is derived,
too high and unwanted side effects or toxicity can occur, endangering the health of the
patient. However when a drug is ingested or injected, the level within the patient's
blood tends to rise up towards a plateau and then after some time falls again to zero
unless more drug is given. In many instances a more efficient application method
would be one that gives a stable level of treatment. Other problems can occur with
drug stability, for example for a drug to be taken orally it must not be degraded by
digestive processes. At the time of writing approximately 15% of the current world
pharmaceutical market consists of products which utilise a carrier system and the US
3market for drug delivery systems is expected to reach $82 billion by 2007 (Roco and
Bainbridge 2002).
To minimise drug degradation and optimise drug delivery, a wide variety of drug
carrier and delivery systems are under investigation and several reviews have been
published on this subject (Langer 1995, 1998, Kaparissides et al 2006).
A number of methods can be utilised to apply various carrier systems:
Ingestion – the drug can be incorporated into a carrier system so that the composite
material can be swallowed. This method is the most popular due to its simplicity and
convenience. The carrier system must be capable of protecting the drug against the
highly acidic medium of the stomach and/or enzymatic degradation throughout the
digestive system. Sometimes the digestive process itself can be utilised to cause
release of the drug. There are, however, a number of problems with this technique
since it can lead to irritation of the bowel and also in many cases the drug must still
penetrate the stomach/intestine wall.
Inhalation – the drug can be dispersed within an aerosol, usually via a nebuliser and in
this way can be directly inhaled. Especially suitable for treating respiratory diseases,
this technique is widely used for the treatment of asthma. However delivery via this
method can still be adversely affected by the barrier between air and blood within the
lung.
4Transdermal – the drug is incorporated within a patch, similar to the nicotine patches
used to relieve “cravings” of people attempting to stop smoking. This method avoids
the problems of degradation of drugs by digestive process and can be used to provide
local delivery e.g. to a wound or skin conditions. Patches often need to be applied
only once every several days and the method is non-invasive and painless. It also has
the advantage that unlike oral and inhalation routes, patches can be easily and safely
applied to unconscious patients. The skin barrier does lead to slow penetration rates
and therefore in many instances only relatively low dosage levels can be attained.
Other problems may include a lack of dosage flexability.
Injection – this technique has the disadvantage of being invasive and can be painful.
Drug carrier systems can be utilised within this method, for example to prevent
degradation of the drug within the bloodstream. As an alternative, a drug/carrier
composite can be surgically implanted close to an affected site.
2.2 Classes of materials
2.2.1 Hydrophilic polymers
The pharmaceutical industry has shown great interest in the development of
controlled release systems based on hydrophilic polymers. Hydrogels represent a
common class of polymers used for drug delivery. In essence a hydrogel is a material
based on polymers such as poly(vinyl alcohol) or poly(acrylic acid) which would
normally be soluble in water. However either during or after the polymer synthesis, a
degree of crosslinking converts the linear polymer chains into a polymer network.
This process renders the polymers insoluble, however the high presence of
hydrophilic groups within the network gives the structure a high affinity for water.
5Although the network does not dissolve, it is capable of adsorbing water with
consequent swelling of the polymer matrix. The nature of the polymer and degree of
crosslinking affects the swelling behaviour. A network with few crosslinks and a large
number of hydrophilic groups will adsorb large amounts of water with a high degree
of swelling. Less hydrophilic monomers, incorporation of hydrophobic co-monomers
or a high degree of crosslinking all act to reduce water adsorption, usually leading to a
firmer, more rigid firmer gel. Due to the fact that they include a high water content,
hydrogels often show high degrees of biocompatibility. The polymer network itself
can be either bio-inert or be a biodegradable polymer network. Natural polymers can
also be used, with for example, hydrogels based on chitosan, alginase or collagen
having been utilised. The application of a wide variety of hydrophilic biodegradable
polymers to delivery of proteins has been extensively reviewed (Gomboltz et al
1995). Typical polymers include hydrogels based on poly(vinyl alcohol),
poly(vinylpyrrolidinone) or cellulose and other natural polymers such as alginase or
collagen. Frequently the drugs, especially if they are biologically derived (such as
proteins) can be quite unstable. Besides enabling the controlled release of the active
material, these hydrogels often act as a stabilizing media for these unstable agents.
For example a drug could be incorporated into a hydrogel either as it is synthesized or
post-synthesis. This can then be applied to the patient via any of the techniques
described above. Once in vivo, the drug is released by a number of means. These
might include simple diffusion or alternatively the polymer may be eroded or
dissolved, for example, by digestion. In an ideal situation this process will occur at a
constant rate leading to continual release of controlled amounts of the drug. If the
polymer is utilised as a transdermal patch or is surgically implanted close to an
affected site, the drug can be delivered where it is most needed.
6A similar method utilises polymers which are actually degraded rather than just
swollen. Examples include polymers which are based on poly(lactide) or
poly(glycolide), (Figure 1), and which are slowly hydrolysed in vivo to release an
active agent, e.g. leuprolide acetate (Ogawa et al 1988).
A polymer must address several criteria before it is suitable for use as a carrier
system. In the case of polymers that are effective in vivo, they must be both
biocompatible and must biodegrade within a reasonable period of time. Irrespective of
the manner of application, the polymer itself and any degradation products must be
non-toxic and must create neither any allergic or inflammatory response. The method
of release is often dependant on the nature of the drug itself; low molecular weight
drugs are capable of diffusing out of the polymeric matrix and if water soluble, will be
rapidly released. However larger molecules such as proteins will not diffuse as readily
and often remain within the hydrogel matrix until the polymer itself is either degraded
or enzymatic digestion releases them. Release rates depend on several factors
including the quantity/dosing of drugs within the composite, the rate of degradation of
the polymer, the water content, (if it is a hydrogel type material), and the presence and
degree of crosslinking.
A property that makes hydrogels exceedingly suitable for drug encapsulation is that
many of the materials used for these systems can be synthesised so as to be responsive
to their environment. A change of pH for example, can lead to protonation or
deprotonation of active groups within the polymer. This can change its affinity for
water, giving us a material whose swelling is pH responsive, thereby affecting many
7of their other physical properties such as permeability. This gives us the opportunity
to design drug release agents which are selectively triggered by certain conditions
- e.g. their responsiveness to pH means they can be designed to release active agents
within a selected part of the digestive tract. Similar smart materials can be designed
which respond to changes in physiological conditions and therefore only release the
drug at times when it is needed. Hydrogels can be designed which respond to other
stimuli as well as pH, such as ionic strength, temperature and electric field. They can
even be designed to respond to the presence or absence of specific analytes.
As mentioned earlier, polymer-based delivery systems allow application of active
agents in many ways including ingestion, transdermal patches, suppositories, ocular
and subcutaneous methods. A few examples are given here: Nitroglycerin is often
used in the treatment of angina, however volatilization of the active component can
lead to loss of tablet activity (Markovich et al 1997). This problem can be mitigated
by the use of a acrylic-based hydrogel as a host for the nitroglycerin and incorporation
of this composite in the construction of a transdermal patch.
There has been wide research into utilising these materials in the treatment of cancer
for, for example the delivery of ara-C for leukaemia. This drug gives rise to a number
of side effects but these are mitigated when a constant infusion of the drug is
introduced subcutaneously. As an alternative approach, crosslinked polyhydroxyethyl
acrylate can be utilised as a host for this material. Discs of this composite display a
steady controllable release of the active material (Teijon et al 1997). A similar
composite based upon polycaprolactone/polyethylene glycol has been used as a
8matrix for the anticonvulsant drug clonazepam. Stable constant release properties
were displayed for over 45 days (Cho et al 1999).
Similar polymers are suitable for localised delivery of pharmaceuticals. In the
treatment of brain cancer, one approach that has been successfully used is surgery to
remove as much of the tumour as possible, followed by placing in the surgical site,
small wafers based on polyanhydrides. These contain the anti-cancer drug carmustine
which is slowly released over a one month period to kill any remaining tumour cells
(Brem et al 1995). Alternatively thermosensitive hydrogels based on block
copolymers of poly(ethylene oxide) and poly(lactide) have been made which are
liquid at 45oC and can be injected directly to the required site. Upon cooling to body
temperature, the gel immediately sets, trapping any pharmaceutical compounds in the
solution, so allowing them to be released slowly (Jeong et al 1997).
The materials mentioned so far are usually based on simple polymeric systems,
however, more complex reactive systems can be designed. As mentioned earlier,
hydrogels can be synthesised which respond to environmental conditions. An example
of this is a “smart” porous membrane made from a polymethacrylic acid/polyethylene
glycol copolymer. This is used as a host for insulin but also contains encapsulated
glucose oxidase. Glucose oxidase specifically catalyses the oxidation of glucose to
gluconic acid, which causes a subsequent pH drop. This leads to shrinkage of the
membrane and the controlled release of insulin in response to hyperglycaemia
(Gander et al 2001). Apart from drug delivery, recent work has focussed on the use of
hydrophilic polymers in gene therapy and has shown that encapsulation of the DNA
9inside a hydrophilic polymer can increase the transfection efficiency (Ottenbrite
1999).
2.2 Natural polymers
Besides synthetic polymers, natural polymers have also been widely studied as drug
carrier agents, especially as for many of them their biocompatibility and non-toxicity
are well known since they form major components of our diets. Proteins are of great
interest due to their wide variety of structures and their easy availability from sources
such as, for example, egg-white, soybean and whey (Chen et al 2006). Hydrogels can
be easily generated from a wide variety of proteins and possess the desirable qualities
of their synthetic analogues. Usually proteins can be gelated by methods such as
heating, which unfolds the polypeptide chains within the protein structure. These then
tend to aggregate forming a three dimensional structure crosslinked by hydrogen
bonding and/or hydrophobic effects (Clark et al 2001). Other methods for inducing
gelation include crosslinking with calcium ions (Maltais et al 2005). A wide variety of
hydrogel morphologies and microstructures can be generated by variation of the
preparation technique (Chen et al 2006). Applications of these gels include controlled
release of tocopherol (Chen et al 2006) from an lactoglobulin based emulsion under
simulated gastric conditions. Other examples include the incorporation of drug
compounds within albumin (Sokolowski and Roger 1984, Tomlinson and Burgen
1985) or corn protein (Liu et al 2005) and a recent review has been published on this
topic (Chen et al 2006).
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2.3 Micelles, vesicles and liposomes
Micelles are formed by a wide range of amphiphilic surfactant molecules in aqueous
solution. A typical amphiphile contains a long alkyl chain and a polar headgroup. In
solution the interactions between the alkyl chains and water are extremely
unfavourable and this drives aggregation of the alkyl chains together to minimise this
interaction. A structure then forms as shown schematically in Figure 2, where a
spherical aggregate spontaneously assembles, with the polar headgroups on the
outside of the sphere and a hydrophobic interior, stabilised by Van der Waals
interactions between the chains.
What makes micelles so useful as carrier agents is that hydrophobic species can be
incorporated within the core of the micelle. This enables the transport of hydrophobic
active agents at concentrations much higher than would be possible for a simple
aqueous solution of these compounds. The hydrophobic environment of the core
moreover protects the guest against hydrolysis and enzymatic degradation.
As an alternative to the classical long chain surfactants shown in Figure 2,
amphiphilic block copolymers are also very adept at forming micellar structures. For
example a block copolymer containing a hydrophobic block such as polystyrene and a
hydrophilic block such as polyethylene oxide, can dissolve in water to give a micellar
structure with a polystyrene core surrounded by a polyethylene oxide corona, with the
whole structure being typically 5-50 nm in diameter. Block copolymers re especially
suitable for this purpose since they are available in a wide variety of molecular
weights. Since a wide variety of monomers and the composition ratios can easily be
selected, this allows fine control of the size, composition and morphology of the
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micelles. Incorporation of many functional groups is easily attained; for example
crosslinking groups can be utilised to stabilise the micelle structure and the surface
properties, selectivity and biocompatibility of the micelles can all be tailored.
In a similar manner, a variety of compounds can be utilised to form vesicles. These
are somewhat more complex structures than micelles (figure 2) in which a spherical
membrane is formed containing an aqueous core. Liposomes are types of vesicles
which are widely used within drug transport and consist of spherical phospholipid
bilayers with an aqueous core and are the most commonly used of these carrier
systems (Langer 1998, Kaparissides et al 2006). They are capable of transporting
either hydrophilic agents within the core - or hydrophobic agents which are
incorporated into the membrane. The membrane itself can be tailored to prevent
access of enzymes to the core, thereby preventing enzymatic degradation, but do
however allow the diffusion out of the active agent. For example channel type
proteins may be incorporated within the membrane and retain their activity, thereby
allowing transport of ions or other small solutes such as drugs through the membrane.
The use of liposomes can lead to a large increase in drug carrying capacity compared
to the use of polymeric systems, however disadvantages can be encountered such as
shorter shelf-life and rapid destruction of the vesicle within the body. The
biocompatabilty of these systems however can be improved by modifying their
surface properties, such as by the attachment of polyethylene glycol units (Park et al
1997, Lasic et al 1999, Moghimi et al 2003). Also, antibodies can be attached to the
surfaces of these systems, allowing them to specifically target sites that require
treatment. Tumours, for example can be targeted by substituting liposomes with
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antibodies against the HER2 proto-oncogene, found in breast and other cancers
(Kirpotin et al 1997, Park et al 1998). Similarly amylopectin can be attached to the
surface of liposomes to enable targeting of lung tissue (Poanini et al 1997).
2.4. Nanotechnology
In recent times, nanotechnology has become an intensely studied field of research.
The application of nanosized materials is expected to make significant advances in
biomedical applications such as drug delivery and gene therapy (Sahoo and
Labhasetwar 2003, Moghimi et al 2001, 2003).
Earlier in this chapter the use of biodegradable polymers as drug carriers was
discussed. Nanoparticles of these types of materials with sizes in the range 10-1000
nm can be synthesised and incorporate drug molecules by way of entrapment or
binding. Similarly, nanocapsules can be synthesised in which a polymer membrane
forms a vesicle-like structure with the drug molecules confined within a central
cavity. Because of their small size, these systems are capable of passing through small
capillaries and be taken up by cells, allowing efficient drug accumulation at a target
size (Desai et al 1997). In these materials size and surface properties determine their
distribution in the body (Sahoo and Labhasetwar 2003). Localised application of these
nanoparticles can be achieved by their tendency to accumulate in tumours due to
enhanced permeation effects; this has been extensively reviewed elsewhere (Maeda
2001). Alternatively the nanoparticles can be delivered locally to the size of interest
such as within a specific artery after balloon angioplasty (Guzman et al 1996) to
deliver long term release (14 days) of dexamethasone.
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Dendrimers are branched polymers grown from a central core with very precisely
controlled degrees of polymerisation, Figure 3 shows a schematic of a fourth
generation dendrimer. This makes their size, composition and molecular controllable
to an exact degree and is an alternative form of polymer nanoparticle to those made
by classical emulsion type polymerisations. There has been great interest in utilising
dendrimers as drug carrier agents because not only can the bulk of the dendrimer be
synthesised exactly but a wide variety of surface groups can be utilised, enabling
further surface functionalisation. Dendrimers for example can be made with
hydrophilic surfaces and hydrophobic interiors or vice versa. Recent reviews on this
subject (Svenson and Tomalia 2005, Gupte et al 2006) extensively detail many of the
most pertinent advances in this field so only a few highlights will be given here.
Dendrimers have been utilized to carry a variety of small molecule pharmaceuticals.
Commercial PAMAM dendrimers have been used to encapsulate the anticancer drug
cisplatin, giving conjugates that exhibited slower release, higher accumulation in solid
tumours, and lower toxicity compared to the free drug (Malik et al 1999). PAMAM
dendrimers which had been functionalised with poly(ethylene glycol) chains had their
encapsulation behaviour for the anticancer drugs adriamycin and methotrexate
studied. Up to 6.5 adriamycin molecules or 26 methotrexate molecules per dendrimer
could be incorporated for one of the materials studied. The drug release from this
dendrimer was slow at low ionic strength but fast in isotonic solution (Kojima et al
2000). Similar dendrimers encapsulated the anticancer drug 5-fluorouracil, showing
reasonable drug loading, and reduced release rate and haemolytic toxicity (Bhadra et
al 2003). Up to 78 molecules of the anti-inflammatory drug ibuprofen molecules were
complexed by PAMAM dendrimers through electrostatic interactions between the
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dendrimer amines and the carboxyl group of the drug. The drug was successfully
transported into lung epithelial carcinoma cells by the dendrimers (Kohle et al 2003).
Other recent studies have also indicated that low generation PAMAM dendrimers
cross cell membranes (El-Sayed et al 2003).
Ceramic nanoparticles have also been studied due to their inherent advantages of ease
of synthesis in a wide variety of sizes, shapes and porosities by methods similar to
sol-gel processes. They are available in very small (<30 nm) sizes making them
capable of crossing cell membranes, possess surfaces which are easily chemically
modified and do not display swelling processes with changes in pH (Sahoo and
Labhasetwar 2003). For example silica nanoparticles can be constructed with an anti-
cancer drug entrapped within their cores (Roy et al 2003) which are stable in aqueous
systems. Tumour cells take up these nanoparticles, which upon irradiation generate
singlet oxygen which significantly damages the tumour cells.
3 Commercial Systems
There are a wide variety of commercial drug carrier agents available; we are only
going to mention a few of these as a complete review would form an article itself.
3.1 Polyanhydrides
As previously mentioned, polyanhydrides are widely used as slow release agents due
to the fact they biodegrade reproducibly and with no toxic by-products. Commercial
products include materials such as Decapeptyl SR®, manufactured by Ipsen Ltd which
contains the active ingredient triptorelin acetate encapsulated in poly(lactide-co-
glycolide). This is utilised in the treatment of prostate cancer. Similar products
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include Lupron Depot® (TAP Pharmaceuticals Inc, active ingredient leuprolide
acetate) and Sandostatin LAR® (Novartis, active ingredient octreotide acetate).
Nitroglycerin is a problematic drug due to its loss of tablet activity, often by
volatilization of the active component (Markovich et al 1997). This can be avoided by
incorporation of the nitroglycerin into an acrylic-based hydrogel which is then
incorporated into a transdermal patch, as exemplified by products such as Deponit®
(Schwarz Pharma), Minitran® (3M Pharma) and Nitrodisc® (G.D. Searle Company).
4. Conclusions
Drug delivery spans a wide variety of fields such as medicine, chemistry, biology and
materials science. As fields such as genomics, proteomics and immunology progress,
we will see these approaches being utilised to target drugs to specific sites with
greater specificity. Further investigation into the transport of drugs across obstacles
such as the blood-brain or air-blood barriers will enable development of simplified
delivery systems for these compounds.
There are a wide number of potential techniques that would prove highly beneficial to
medical practitioners and are currently being widely researched, some of which are
listed below.
1. Biodegradable nanoparticles and methods for producing them.
2. More complex controlled release characteristics, for example in response to
changing physiological conditions.
3. Delivery of large quantities of drugs in controlled and highly localised
manner, for example to destroy a tumour without harming surrounding healthy
tissue.
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4. Biodegradable coatings for implants, for example, for the release of agents
that minimise rejection and/or promote healthy cell growth.
5. Functionalising the delivery system to enable selective targeting of sites via
immunochemical response.
There are many future opportunities in this field, with one of the most exciting being
the application of nanotechnology to drug delivery. The potential advantages
associated with nanoparticles such as easy tailoring of properties such as size, often
easy transition across cell membranes and potential site specificity ensures these
approaches will be intensively studied. Problems to be overcome include the fact that
these materials can be cytotoxic and often display poor stability in biochemical
environments (Kaparissides et al 2006). However, these are challenges to be
overcome and it can be seen that with the advances taking place in chemistry,
materials, biology and other sciences that sooner or later they are likely to be
achieved.
5. Biosensors
5.1 History and format of biosensors
The purpose of this chapter is to introduce the concept of using biological molecules
as the selective recognition elements within biosensors. Most sensors consist of three
principle components, as described below and shown in figure 4:
i. The first of these includes a receptor species, usually biological in origin
such as an enzyme, antibody or DNA strand capable of recognising the
analyte of interest with a high degree of selectivity; this is usually
concurrent with a binding event between receptor and analyte.
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ii. The second component that must be present is a transducer, enabling the
translation of the binding event into a measurable physical change;
possible events include the generation of electrons, protons, an
electrochemically active chemical species such as hydrogen peroxide or
simple physical changes such as a change in conductivity, optical
absorbance or fluorescence.
iii. Thirdly there must be inclusion of a method of measuring the change
detected at the transducer and converting this into useful information.
There are several advantages associated with using biological molecules as the active
recognition entity within a sensor. Usually they display unsurpassed selectivities; for
example glucose oxidase will interact with glucose and no other sugar, and in this
way will act as a highly selective receptor. In the case of glucose oxidase, the
electrochemically inactive substrate glucose is oxidised to form gluconolactone along
with the concurrent generation of the electroactive species hydrogen peroxide.
Enzymes also generally display rapid turnover rates and this is often essential to (a)
avoid saturation and (b) to allow sufficient generation of the active species in order to
be detectable.
Antibodies bind solely to their antigens and achieve specificity via a complex series
of multiple non-covalent bonds. Since the principle of immunoassay was first
published by Yalow and Berson in 1959, there has been an exponential growth in both
the range of analytes to which the technique has been successfully applied and the
number of novel assay designs. Development of enzyme-labelled immunoanalytical
techniques e.g. Enzyme-Linked Immuno Sorbent Assay (ELISA) has provided
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analytical tests without the safety risks associated with radiolabelling-based
techniques.
The rapid measurement of analytes of clinical significance e.g. towards various
disease markers would permit earlier intervention, which in a medical setting is
frequently of utmost importance. There has been much research on the development
of direct immunosensors that do not rely on the use of a detectable label. Such a
system will lead to simpler assay formats and ideally lower times of detection. A
reusable and rapid detection system would, moreover, allow for continuous real-time
measurement, so helping to maintain optimal homeostatic conditions.
Unfortunately there are also some disadvantages related to the construction and use of
biosensors. Often the biological species can either be extremely expensive or difficult
to isolate in sufficient purity. Immobilisation of these species can lead to loss of
activity and the presence of various chemical species in the test solution can also
cause loss of activity e.g. enzymes can be easily poisoned by heavy metals. In
biological samples such as blood or saliva, there can also be solutes that are
electrochemically active and interfere with determinations of the target species. Again
in physiological fluids such as blood, various species may be present which bind to
the surface so causing fouling and loss of sensor response.
Antibody-antigen binding is based on multiple non-covalent interactions, and
therefore there are no newly formed molecules, protons or electrons that are easily
detectable, which has limited the development of direct antibody affinity-type sensors.
Also affinity binding constants typically range from 105 to 1011 mol. l-1 meaning that
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the antibody-antigen binding event is often irreversible. As a consequence of this,
many contemporary immunosensors are only of use for “single-shot” analyses and
must be disposable in nature.
5.2 Glucose biosensors
A series of extensive reviews on biosensors and their history have been published
elsewhere (Hall 1990, Eggins 1996, Wang 2001) and therefore only a brief history
will be given here. Easily the most intensively researched area has been towards the
development of glucose biosensors (Wang 2001, Newman et al 2004). The reason for
this is the prevalence of diabetes which has become a world-wide public health
problem. Diabetes represents an increasing epidemic with at the time of writing 170
million sufferers world-wide (World Health Organisation, www.who.org), and this is
estimated to reach 300 million by 2045 (Newman et al 2004). Diabetes is related to a
number of factors such as obesity and heart disease all of which make this disease one
of the leading causes of death and disability in the world. The world market for
biosensors is approximately $5bn with at the time of writing approximately 85% of
the world commercial market for biosensors being for blood glucose monitoring
(Newman et al 2004).
These factors have lead to the development of a number of inexpensive disposable
electrochemical biosensors for glucose, incorporating glucose oxidase (GOD) bound
immobilised at various electrodes. They are generally amperometric sensors, with
electrodes polarised at a set potential; the oxidation or reduction of a chosen
electroactive species at the surface will then lead to generation of a detectable current.
The principle classes of glucose and other types of biosensors are described below.
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5.3 First generation biosensors
The first electrochemical glucose biosensor was based on an oxygen electrode (Clark
and Lyons 1962). A film of immobilised glucose oxidase was laid down upon the
oxygen electrode, which was overlaid with a semipermeable dialysis membrane.
Upon exposure to glucose, the enzymatically catalysed oxidation reaction occurs,
causing a localised consumption of oxygen.
Glucose oxidase
Eqn. 1. glucose + O2  Gluconolactone + H2O2.
This then leads to a drop in the current generated at the oxygen electrode. This device
was subject to fluctuations caused by variable oxygen levels, however, further work
(Updike and Hicks 1967) utilised two oxygen electrodes, one of which was coated
with glucose oxidase. Measurement of differential current between the two electrodes
served to cancel out these effects. The first commercial glucose analyzer was the
Model 23 YSI analyzer, launched by the Yellow Spring Instrument Company in 1975
and based on the Clark electrode. This device was capable of measuring the glucose
level in 25 ml of whole blood.
The Clark oxygen electrode to monitor the depletion of oxygen caused by the
oxidation of glucose is an example of a first generation biosensor, where the reaction
causes depletion of an electrochemically active compound (oxygen) which can then
be measured. An alternative technique is based on the amperometric monitoring of the
product of the enzyme catalysed reaction, H2O2; Eqn. 2.
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+650 mV vs Ag/AgCl
Eqn. 2. H2O2  2H+ + O2 + 2e-
The results from these types of sensors can be affected by fluctuations in the ambient
oxygen concentration or by the presence of electroactive species such as ascorbate,
that are capable of being oxidised at +650 mV - giving rise to an erroneous result.
Concentration of interferents at the electrode surface can be minimised by application
of a permselective coating to the sensor, thereby reducing interference from
electroactive species. Polymeric materials have led the way with materials such as the
fluorinated ionomer Nafion (Turner and Sherwood 1994) and cellulose acetate
(Maines and Vadgama 1993) being two of the most commonly used. A beneficial
side-effect is that these materials can also confer a degree of biocompatibility. An
alternative approach has been to electropolymerise suitable monomers to form
protective coatings. 1,2-diaminobenzene (Myler et al 1997), for example, when
deposited at the bioelectrode surface serves to both stabilise the electrode due to its
inherent high biocompatibility whilst also imparting selective exclusion of interferents
such as ascorbate.
The robustness of these types of sensors and, after suitable cleaning procedures,
capability for multiple analyses makes them suitable for use within hospitals.
However, diabetes as a condition requires regular monitoring of blood glucose levels,
so hospital analysis is impractical for a normal lifestyle. The obvious solution has
been the development of inexpensive home detection methods where the
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physiological sample, usually blood, can be analysed by the patient. The problems of
cleaning the sensor are moreover negated by using disposable sensor strips.
5.4 Second generation biosensors
As shown earlier, the reaction of glucose oxidase with glucose gives rise to the
formation of gluconolactone and the reduced form of the enzyme, which is then
reoxidised by oxygen. Direct transfer of electrons from the electrode would
circumnavigate this reaction, however the active site of glucose oxidase is encased in
a protein sheath which inhibits this transfer. To facilitate this transfer, a suitable
chemical species can be utilised to "shuttle" electrons back and forth between active
site and electrode. This moiety, known as a mediator must react readily with the
enzyme to avoid competition by ambient oxygen and in both its reduced and oxidised
forms, be stable and preferably require as low an over-potential to be oxidised, as is
feasible. This method sidesteps problems associated with detecting species such as
oxygen or peroxide and also lowers the potential required for measurement of the
enzyme catalysed reaction, thereby reducing the inference by redox active species
present within the sample to be studied. A typical reaction scheme (Fig. 5) where a
ferrocene compound acts as mediator is shown (Cass et al 1984). The first home
glucose testing kit, the Exactech® glucose biosensor is based on this chemistry. The
actual pen sized device is produced by Medisense® and utilises a disposable strip
upon which a single drop of blood is placed. A wide range of glucose sensors (Wang
2001) based on this method have since become commercially available for home
glucose testing. Further work has concentrated on reducing blood volumes and
produced devices such as the Pelikan® device which only require microlitre blood
volumes (Newman et al 2004).
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5.4 Third generation sensors
Second generation biosensors are still somewhat limited in that they require use of a
suitable mediator. Attempts have been made to circumvent this by developing
methods to electronically directly connect or “wire” the enzyme to the electrode,
thereby allowing simple electron transfer from the enzyme to the electrode without
the requirement for a mediator. Although these types of devices have not as yet been
developed commercially, they provide a possible alternative to mediated electron
transfer.
Typical approaches involve the use of a polymeric coating which both immobilises
the glucose oxidase and allows electron transfer to the electrode. One example is the
use of polyvinyl pyridine where the synthetic polymer has been modified with a large
number of osmium based electron transfer relays (Degani and Heller 1987, Ohara et
al 1994). The polymer is co-immobilised at an electrode with glucose oxidase. When
the enzyme reacts with glucose and is converted to the reduced form, the polymer
allows facile transfer of electrons to convert it back to the oxidised form. Similar
materials based on polyvinyl imidazole has also been utilised (Mano et al 2005).
Glucose oxidase and other enzymes have also been immobilised on various electrodes
by a variety of chemical and physical methods (Davis and Higson 2005).
Conducting polymers are especially suitable for the immobilisation of enzymes at
electrode surfaces and have been reviewed in greater details elsewhere (Gerard et al
2002, Barisci et al 1994). A variety of monomers such as pyrrole or aniline can be
electropolymerised on an electrode surface and under correct conditions form stable
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conductive films. If during this electropolymerisation process, enzymes are present in
the solution they can be entrapped within the film during the deposition process,
alternatively they can be adsorbed onto - or be chemically grafted to the film
following deposition (Gerard et al 2002, Barisci et al 1994). The close association
between the conductive polymer and the enzyme facilitates rapid electron transfer
between the enzyme and an electrode surface.
One of the first methods involved the simple entrapment of enzymes such as glucose
oxidase within polyaniline films (Cooper and Hall 1992). Our group has taken this
process further, utilising both non-conductive and conductive polymers to fabricate
arrays of conductive microelectrodes with entrapped biological molecules such as
glucose oxidase (Barton et al 2004).
6. Continuous Monitoring
One problem with the current commercial biosensors is the invasive procedure,
requiring frequent withdrawal of blood for testing which can be both tedious and
painful. Devices which could be implanted within the human body would negate this
aspect of glucose testing. Implantable sensors suitable for in vivo glucose monitoring
require the device to be extremely small and show long-term stability (with minimal
drift thereby removing the need for frequent calibration), display no oxygen
dependency and also show high biocompatibility. The problem of biocompatibility
has been the most elusive of these targets and as yet in vivo glucose sensors have only
limited lifetimes. Effects on sensor performance include fouling by protein deposition
on the surface or formation of fibrous tissue around the sensor (D'Orazio 2003)
leading to loss of sensor performance. Rejection by the immune system or thrombus
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formation if used intravascularly can also degrade device performance and risk harm
to the user.
Subcutaneously applied sensors have been developed (Bindra et al 1991, Henry 1998)
which could monitor glucose concentrations and also be changed by the user.
However the effects of biofouling mean their use was limited to periods of 1–2 weeks.
Again, fouling of the sensor and its effect on sensor performance is a major
consideration. Attempts have been made to improve this using polymeric coatings.
For example, a needle based electrochemical probe coated with Nafion has been
developed (Moussy et al 1993) which is just 0.5 mm in diameter and can be inserted
subcutaneously through an 18-gauge needle. Again in vivo measurements could be
carried out over periods of 2 weeks.
A different approach has been to implant a microdialysis fibre into subcutaneous
tissue and an iso-osmotic electrolyte solution pumped through the fibber. Glucose
diffuses into the fibre and the electrolyte. If flow rates are kept constant the glucose
concentration in the outflow from the fibre can be directly related to the glucose
concentration in the interstitial fluid. Rapid changes in blood glucose concentration
can be determined although there is a time delay, typically about 8 minutes (Janssen
et al 1988) between changes in blood and interstitial fluid concentrations. The use of
these probes combined with glucose biosensors to monitor the outflow have achieved
4–7 days continuous use for glucose monitoring in humans (Myerhoff et al 1992,
Hashiguchi et al 1994).
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A subcutaneously implantable device, the CGMS® (Continuous Glucose Monitoring
System) has been commercialized by Minimed (www.minimed.com). The glucose
biosensor probe is inserted just beneath the skin, usually in the abdomen, and can be
used to monitor glucose for up to 72 h, with a reading every 5 min. Traditional blood
sampling of glucose is used to calibrate the device. Other data such as meal times and
exercise periods can also be recorded using the device and all data then downloaded
to a PC.
Non-invasive glucose monitoring systems are an active area of research. Techniques
such as reverse iontophoresis, where a low electric current "pulls" interstitial fluid
through the skin and onto a glucose biosensor negate the need for blood withdrawal.
This technique has been utilised in the GlucoWatch® G2™ Biographer (Cygnus), a
commercially available biosensor device for continuous glucose monitoring. The
electric current pulls the interstitial fluid through the skin and collects it into two gel
discs. These are in contact with an electrochemical glucose biosensor, which
determines the glucose level. Again the device is calibrated using traditional blood
testing. The device records glucose levels every 10 minutes for up to 13 h and can
also sound an alert should the level stray outside predetermined levels. After 13 hours,
the active part of the sensor (i.e. gel pads and biosensor) can be replaced and the
device reused. 95% of GlucoWatch® G2TM Biographer readings are clinically
accurate or acceptable (Newman et al 2004). However there are some problems,
according to the company brochure the Glucowatch may be effected by excessive
perspiration and can cause minor skin irritation. The Glucowatch is now supplied by
Animas Technologies.
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7. Future Needs
This is a brief section just to highlight several potential future applications which,
although not in the current marketplace, are the subjects of intensive research efforts.
7.1 Point of care tests
Although the biosensor market is dominated by glucose testing applications, there is
great interest in developing simple tests for a wide variety of medical problems which
can be easily applied by the patient and detect physical problems which are beginning
to occur whilst still in an early stage, thereby enabling the patient to seek early
medical help. An example of this is the Multisense® system developed by Oxford
Biosensors (www.oxfordbiosensors.com) and soon to be commercialised which
detects early markers of coronary heart disease. Heart disease is a major killer in the
western world and the risk of developing this condition is known to be related to
factors such as diet, smoking, weight and high blood cholesterol.
The Multisense® systems is based on a hand-held device with disposable
electrochemical test strips. Each strip contains several sensors which individually
sense for cholesterol (high density and low density lipoprotein) and triglycerides.
Testing utilises a single drop of blood in the same manner as a glucose sensor. This
will enable fast and simple screening, diagnosis and monitoring of patients who are at
risk of heart disease.
7.2 Artificial pancreas
For many diabetes type 1 sufferers, life is a constant round of glucose testing and
insulin injections. Externally worn insulin pumps have been developed, such as those
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by Medtronic (www.minimed.com). These have the advantage that they remove the
need for injections by introducing insulin subcutaneously though a canella. When
coupled together with a glucose biosensor, there is then the potential for the device to
inject insulin "on demand". This was the first device of its type to receive FDA
approval (Newman et al 2004). At present, current commercial devices usually can
only be used for a few days at a time without maintenance and injection and sensing
sites need to be changed regularly. An implanted device which automatically responds
to changes in glucose levels would in effect act as an artificial pancreas and improve
quality of life for many millions of people.
7.3 Warfarin monitors
Warfarin is routinely prescribed as an anti-coagulation agent for patients with an
increased tendency for thrombosis or as prophylaxis in those individuals who have
already formed a blood clot (thrombus) which required treatment. However warfarin
when given in too high a dose inhibits natural clotting, leaving the patient subject to
uncontrolled bleeding, both externally and gastrointestinal bleeding. At present,
patients placed on warfarin require their blood to be regularly tested to ensure the
clotting ability of their blood falls within required ranges (Poller et al 2003). This
requires withdrawal of blood and testing within a laboratory environment. Since
warfarin is one of the world's most proscribed drugs, a simple home test which could
monitor warfarin levels or alternatively monitor blood clotting ability would have a
huge global market.
8. Conclusions
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As can be seen biosensors are a rapidly expanding field of research. Currently the
market is dominated by glucose sensing. Many other applications such as cholesterol
monitoring, monitors for various drug treatments and many other analytes are being
intensively researched. It is likely that some of these applications will soon be
commercialised.
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Figures.
Figure 1. Structures of (a) poly(glycolide), (b) poly(lactide).
Figure 2. Structures of (a) a micelle, (b) a vesicle.
Figure 3. Schematic structure of a fourth generation dendrimer.
Figure 4. Schematic of a biosensor.
Figure 5. The oxidation of glucose at an electrode, mediated by a ferrocene derivative.
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